{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:14:53Z","timestamp":1761920093799},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["14095"],"award-info":[{"award-number":["14095"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Molecular Clinical Oncology Special Program","award":["9965"],"award-info":[{"award-number":["9965"]}]},{"name":"European Commission's 7th Framework programme","award":["EU FPT7"],"award-info":[{"award-number":["EU FPT7"]}]},{"name":"MIUR PRIN"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.leukres.2015.11.001","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T16:47:07Z","timestamp":1452530827000},"page":"93-104","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Targeting B-cell non Hodgkin lymphoma: New and old tricks"],"prefix":"10.1016","volume":"42","author":[{"given":"Antonio Giovanni","family":"Solimando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Ribatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"February (18)","key":"10.1016\/j.leukres.2015.11.001_bib0005","first-page":"189","article-title":"Expanded use of rituximab in the management of non-Hodgkin lymphoma","volume":"2","author":"Eichenauer","year":"2009","journal-title":"Onco Targets Ther."},{"issue":"January\u2013February (1)","key":"10.1016\/j.leukres.2015.11.001_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"May (21)","key":"10.1016\/j.leukres.2015.11.001_bib0015","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"September (12)","key":"10.1016\/j.leukres.2015.11.001_bib0020","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"October (1)","key":"10.1016\/j.leukres.2015.11.001_bib0025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol."},{"issue":"December (2)","key":"10.1016\/j.leukres.2015.11.001_bib0030","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"February (4)","key":"10.1016\/j.leukres.2015.11.001_bib0035","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood."},{"issue":"May (5)","key":"10.1016\/j.leukres.2015.11.001_bib0040","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"December (3)","key":"10.1016\/j.leukres.2015.11.001_bib0045","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"January (9759)","key":"10.1016\/j.leukres.2015.11.001_bib0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"April (2)","key":"10.1016\/j.leukres.2015.11.001_bib0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Mechanism of action","volume":"47","author":"Weiner Rituximab","year":"2010","journal-title":"Semin Hematol."},{"key":"10.1016\/j.leukres.2015.11.001_bib0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2007.1.226","article-title":"Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects","author":"Maloney","year":"2007","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"June (2)","key":"10.1016\/j.leukres.2015.11.001_bib0065","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"issue":"January\u2013February (1)","key":"10.1016\/j.leukres.2015.11.001_bib0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"April (16)","key":"10.1016\/j.leukres.2015.11.001_bib0075","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"},{"issue":"November (3)","key":"10.1016\/j.leukres.2015.11.001_bib0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.12537","article-title":"A multicentre, phase II trial of ofatumumab monotherapy in relapsed\/progressive diffuse large B-cell lymphoma","volume":"163","author":"Coiffier","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"March (5)","key":"10.1016\/j.leukres.2015.11.001_bib0085","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-11-0850","article-title":"Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in Fc\u03b3RIIIa-genotyped patients with previously treated follicular lymphoma","volume":"18","author":"Forero-Torres","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"August (23)","key":"10.1016\/j.leukres.2015.11.001_bib0090","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"August (7)","key":"10.1016\/j.leukres.2015.11.001_bib0095","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood"},{"issue":"April (5)","key":"10.1016\/j.leukres.2015.11.001_bib0100","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/leu.2012.252","article-title":"Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in","volume":"27","author":"Goede","year":"2013","journal-title":"Leukemia"},{"issue":"August (24)","key":"10.1016\/j.leukres.2015.11.001_bib0105","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"February (2)","key":"10.1016\/j.leukres.2015.11.001_bib0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0091270012436560","article-title":"Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I\/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer","volume":"53","author":"Wynne","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"April (1\u20133)","key":"10.1016\/j.leukres.2015.11.001_bib0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0169-409X(98)00099-4","article-title":"Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography","volume":"37","author":"Moghimi","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.leukres.2015.11.001_bib0120","unstructured":"A. Salar, R. Bouabdallah, C. McIntyre, et al., A pharmacokinetic study of subcutaneous and intravenous mabthera (rituximab) in patients with follicular lymphoma. wwwclinicaltrialsgov (2010)."},{"key":"10.1016\/j.leukres.2015.11.001_bib0125","doi-asserted-by":"crossref","unstructured":"A. Salar, I. Avivi, J.C. Larouche, et al. Final Results of the BP22333 Study Demonstrate non-inferior pharmacokinetics (PK) and safety of subcutaneous (SC) administration of rituximab compared with intravenous (IV) administration as maintenance therapy in patients with follicular lymphoma (FL) 54th ASH Annual Meeting and Exposition. (December (8)) (2012) (Abstract 079).","DOI":"10.1182\/blood.V120.21.1641.1641"},{"issue":"March (3)","key":"10.1016\/j.leukres.2015.11.001_bib0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2015.11.001_bib0135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"January (30)","key":"10.1016\/j.leukres.2015.11.001_bib0140","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.leukres.2015.11.001_bib0145","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"July (7)","key":"10.1016\/j.leukres.2015.11.001_bib0150","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2015.11.001_bib0155","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5891","key":"10.1016\/j.leukres.2015.11.001_bib0160","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.leukres.2015.11.001_bib0165","unstructured":"Goekbuget N, Dombret H, Bonifacio M, et al., ASH Annual Meeting and Exposition, San Francisco, CA. December 6\u20139, (2014) (Abstract 379)"},{"issue":"Jan (1)","key":"10.1016\/j.leukres.2015.11.001_bib0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10428194.2014.911859","article-title":"Phase 1\/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fc\u03b3RIIIa Patients with Previously Treated Follicular Lymphoma","volume":"56","author":"Ganjoo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2015.11.001_bib0175","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-014-0058-4","article-title":"New antibody approaches to lymphoma therapy","volume":"7","author":"Suresh","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"December (3)","key":"10.1016\/j.leukres.2015.11.001_bib0180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.leukres.2015.11.001_bib0185","doi-asserted-by":"crossref","unstructured":"A. Viardot, M. Goebeler, R. Noppeney, et al., Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma, ASH Annual Meeting 1637 (2011) (Abstract 118).","DOI":"10.1182\/blood.V118.21.1637.1637"},{"issue":"5","key":"10.1016\/j.leukres.2015.11.001_bib0190","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.hoc.2008.07.004","article-title":"Molecular biology and genetics of lymphomas","volume":"22","author":"Hartmann","year":"2008","journal-title":"Hematol.\/Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2015.11.001_bib0195","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/302570","article-title":"Novel therapies for aggressive B-cell lymphoma","volume":"2012","author":"Foon","year":"2012","journal-title":"Adv. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2015.11.001_bib0200","first-page":"56","article-title":"Antibody drug conjugates: potent weapons for the oncology arsenal","volume":"27","author":"Rohrer","year":"2009","journal-title":"Chemistry Today."},{"issue":"4856","key":"10.1016\/j.leukres.2015.11.001_bib0205","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamin \u03b31(I): an antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.leukres.2015.11.001_bib0210","first-page":"108","article-title":"Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase I study","author":"Fayad","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.001_bib0215","first-page":"112","article-title":"Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1 \/2 study","author":"Fayad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.001_bib0220","first-page":"116","article-title":"Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab in relapsed DLBCL patients followed by stem cell transplantation: preliminary safety and efficacy","author":"Wagner-Johnston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.001_bib0225","first-page":"116","article-title":"Phase 1 study of anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) plus rituximab in Japanese patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","author":"Hatake","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2015.11.001_bib0230","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I\/II study in non-Hodgkin's lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.11.001_bib0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.smim.2007.12.007","article-title":"Germinal center structure and function: lessons from CD19","volume":"20","author":"Carter","year":"2008","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.leukres.2015.11.001_bib0240","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.leukres.2015.11.001_bib0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","article-title":"The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity","volume":"6","author":"Tedder","year":"1997","journal-title":"Immunity."},{"issue":"March (91)","key":"10.1016\/j.leukres.2015.11.001_bib0250","article-title":"Tetraspanins as therapeutic targets in hematological malignancy: a concise review","volume":"6","author":"Beckwith","year":"2015","journal-title":"Front Physiol."},{"issue":"November (11)","key":"10.1016\/j.leukres.2015.11.001_bib0255","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3109\/10428194.2013.782612","article-title":"Time to look for CD30 expression in diffuse large B-cell lymphomas, along the way to immunotherapy","volume":"54","author":"Vega","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"August (8)","key":"10.1016\/j.leukres.2015.11.001_bib0260","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"April (14)","key":"10.1016\/j.leukres.2015.11.001_bib0265","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"September (9)","key":"10.1016\/j.leukres.2015.11.001_bib0270","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3109\/10428194.2011.574761","article-title":"CD30: an important new target in hematologic malignancies","volume":"52","author":"Deutsch","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"February (9)","key":"10.1016\/j.leukres.2015.11.001_bib0275","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"February (9)","key":"10.1016\/j.leukres.2015.11.001_bib0280","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1182\/blood-2015-01-622480","article-title":"CD30: seeing is not always believing","volume":"125","author":"Blum","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.001_bib0285","unstructured":"Clinicaltrials.gov: NCT01925612."},{"key":"10.1016\/j.leukres.2015.11.001_bib0290","unstructured":"Clinicaltrials.gov: NCT01805037."},{"key":"10.1016\/j.leukres.2015.11.001_bib0295","unstructured":"Clinicaltrials.gov: NCT01994850."},{"issue":"September (15)","key":"10.1016\/j.leukres.2015.11.001_bib0300","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1158\/0008-5472.CAN-05-4101","article-title":"The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner","volume":"66","author":"Hsu","year":"2006","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.leukres.2015.11.001_bib0305","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000109","article-title":"Oncogenic activation of NF-kappaB","volume":"2","author":"Staudt","year":"2010","journal-title":"Cold Spring Harb. Perspect Biol."},{"issue":"18","key":"10.1016\/j.leukres.2015.11.001_bib0310","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2015.11.001_bib0315","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1809.1809","article-title":"Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"122","author":"Pro","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.001_bib0320","unstructured":"Clinicaltrials.gov: NCT01192464."},{"issue":"July (1)","key":"10.1016\/j.leukres.2015.11.001_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2015.11.001_bib0330","article-title":"Preliminary results of a phase I study of nivolumab (BMS -936558) in patients with relapsed or refractory lymphoid malignancies","author":"Lesokhin","year":"2014","journal-title":"ASH"},{"issue":"May (10)","key":"10.1016\/j.leukres.2015.11.001_bib0335","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"January (1)","key":"10.1016\/j.leukres.2015.11.001_bib0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T20:52:04Z","timestamp":1600030324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615305415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":68,"alternative-id":["S0145212615305415"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting B-cell non Hodgkin lymphoma: New and old tricks","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}